A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Decitabine (Primary) ; NTBI 1301 (Primary) ; NTBI 1301 (Primary) ; Aldesleukin; Cyclophosphamide
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 13 Dec 2017 Planned End Date changed from 31 Oct 2020 to 15 Aug 2020.
- 13 Dec 2017 Planned primary completion date changed from 31 Oct 2019 to 15 Aug 2019.
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.